MGMT and central nervous system cancer: There are inherent biases to such single-institution retrospective studies which can introduce confounding factors such as inclusion of varied patient populations (e.g., inclusion of grade III gliomas, low performance status patients, unknown MGMT status), differences in treatment (e.g., RT above and below standard 60 Gy).